Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
about
Redox-directed cancer therapeutics: molecular mechanisms and opportunitiesAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersTargeting Hsp90 in urothelial carcinomaIdentification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screeningHsp90 blockers inhibit adipocyte differentiation and fat mass accumulationIntra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanomaSynergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices.A modified HSP70 inhibitor shows broad activity as an anticancer agent.Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs.To fold or not to fold: modulation and consequences of Hsp90 inhibition.Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinomaEvaluating melanoma drug response and therapeutic escape with quantitative proteomicsHSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible waySafety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinA screening assay to identify agents that enhance T-cell recognition of human melanomasHSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansHeat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsThe HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsModulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Macrocyclic inhibitors of hsp90Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomasThe human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cellsHsp90 molecular chaperone inhibitors: are we there yet?BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability.Small-molecule proteostasis regulators for protein conformational diseases.Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsThe Akt signaling pathway: an emerging therapeutic target in malignant melanoma.NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAGSynergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micellesAutophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.
P2860
Q24645584-9CF6D5AA-CC9C-47AA-A52F-2C8BFB30AD74Q27022514-5AB2C611-6A30-40BE-B060-E8129464622EQ27023406-69C57188-40A6-4BE0-A4C4-6DCDAAE3703CQ28485925-8AB9E390-5E30-4863-8313-E6EFBCDBCFECQ28542000-9303E83D-46E0-4502-BE3B-0C8F221F8254Q28740547-3D0BF730-FF74-49E9-9566-4C01B96A519BQ30533630-EB582E5E-27B5-4352-B36C-36F926DB390CQ30537961-ED9C2EDB-3710-4FDA-8A2F-96D13581F625Q33437949-1016CC1C-F286-451E-BDC8-26A6FFCD3DB2Q33531705-194441DD-DBA8-433B-9901-DCE6B7C8F2EAQ33668999-12664061-335C-43B2-832C-DBE12CFF25DDQ33710107-5A5528EF-D0CC-4B3C-8929-777B4F9A3729Q33757003-153E08DB-B333-4751-8371-17DC4B0953C0Q33850665-12452AFF-3694-4668-9F87-DDFDEE47C206Q33864144-23ADD3AE-AAA2-40FA-99B9-B00FD9CB448CQ34018372-7A9FAAC9-DC16-431B-B07A-2EA497A9733BQ34074758-C9C6E16A-3C86-467B-954E-F8F7F5382881Q34162151-559C3819-0549-49FD-9A11-7D9052D1FACFQ34164027-0DCA4F74-3971-41A3-AD91-AAC29BF27BC9Q34165045-BBC0983E-45AF-4A6E-8DDE-72D8E1E0142AQ34249948-D5B7F291-0EFB-4F1F-BAD6-CC6A61684AA5Q34475748-7F538005-B879-489B-AD53-20F92955EFD6Q34628001-AF81CED4-2808-4D5B-9D6A-61C7EDB32C86Q34957090-6B653DCD-9125-436A-B200-C95CCB3E6805Q35017513-20BD963B-3167-4E08-B73C-2A0E77196DF0Q35196261-774B8211-70E6-4759-BBED-4BD9093D2FCFQ35444159-EE573806-EBE8-4779-96E8-1952821ED404Q35517613-964EB51B-9BD1-4D34-8826-DA8933C7EE54Q35655105-8B379238-4B85-4B86-871B-E89C21066D54Q35677312-CD508F72-BDE5-4AC9-AA36-E39873EC92BDQ35683088-A95F1C84-0DB0-4E93-9ECA-94A7344F494EQ35823157-BC39809F-4F0F-4746-B71B-588EAFB29C7DQ35911227-0A86ECB2-6D9D-4DA4-8BB6-EACED22F5B85Q35979667-0886F4B6-BA25-4D8D-B728-1D1381C25353Q36501393-38AD634B-BDE7-469D-BF54-A45089259ABEQ36556257-2C2EE6C6-9D76-4D15-A0AC-DC7FD898AC6CQ36680209-E5F35879-CE5F-435C-A8B0-6EC4B87A8E10Q36926960-75013116-FD93-46BF-B35C-C253150EA335Q37092020-A7A464DE-6A7B-43B9-9C08-9CDA36FEBFF4Q37204596-77C22A1C-AAB5-4805-8D12-394658481AE9
P2860
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II trial of 17-allylamin ...... ents with metastatic melanoma.
@en
Phase II trial of 17-allylamin ...... ents with metastatic melanoma.
@nl
type
label
Phase II trial of 17-allylamin ...... ents with metastatic melanoma.
@en
Phase II trial of 17-allylamin ...... ents with metastatic melanoma.
@nl
prefLabel
Phase II trial of 17-allylamin ...... ents with metastatic melanoma.
@en
Phase II trial of 17-allylamin ...... ents with metastatic melanoma.
@nl
P2093
P2860
P1476
Phase II trial of 17-allylamin ...... ients with metastatic melanoma
@en
P2093
Daniel Coit
David B Solit
David Polsky
F Joseph Germino
Iman Osman
James S Goydos
Jedd D Wolchok
Jerrold Teitcher
Katherine S Panageas
Neal Rosen
P2860
P304
P356
10.1158/1078-0432.CCR-08-1002
P407
P50
P577
2008-12-01T00:00:00Z